|
Comparison of Basal and Stimulated Serum Thyroglobulin Levels for Assessing Response to Treatment in Papillary Thyroid Carcinoma
|
A Gholami    , H Gholinia , SH Mousavie Anijdan * |
| 3.Department of Radiation Technology, Faculty of Allied Medical Sciences, Babol University of Medical Sciences, Babol, I.R.Iran. , shmosavia@gmail.com |
|
|
Abstract: (62 Views) |
Background and Objective: Papillary thyroid carcinoma (PTC) is the most common differentiated thyroid carcinoma. Persistent or recurrent disease occurs in approximately 20% of patients after treatment. Measurement of serum Tg level is one of the most important methods used for residual or recurrent disease. The aim of this study was to investigate the role and significance of comparing the two methods of measuring basal thyroglobulin (BTg) and stimulated thyroglobulin (STg) in assessing response to treatment and follow-up of patients.
Methods: In this retrospective study, patients were classified into three categories: excellent response (ER), indeterminate (IR), and biochemically incomplete response (BIR) based on imaging tests and Tg levels. The primary variable was the change in response to treatment one year after initial treatment, as measured by STg versus BTg. Clinical outcomes were assessed based on their final status and disease-free survival time.
Findings: A total of 126 patients, 96 women and 30 men, were enrolled in the study. One year after initial treatment, 28 patients (22.2%) showed a change in classification when the response to treatment was compared with BTg based on STg. Sixteen patients (12.7%) had a worse response, so that they were classified from the ER group to other groups. After measuring STg, structural recurrence was identified in 5 patients during the follow-up period. Based on STg, the highest recurrence was in the BIR group (18.8%) followed by the IR group (10.5%), which was statistically significant compared with the ER group (p=0.001).
Conclusion: This study shows that measurement of STg compared to BTg in low- or intermediate-risk patients better defines treatment response when classified as indeterminate (IR and BIR). However, when BTg gives an excellent response (ER group), STg measurement is not required. |
|
| Keywords: Differentiated Thyroid Carcinoma, Radioactive Iodine, Stimulated Thyroglobulin, Basal Thyroglobulin, Total Thyroidectomy. |
|
|
|
Type of Study: Research |
Subject:
Nuclear Medicine
Received: 2024/11/10 | Accepted: 2025/01/20
|
|
|
|
|
|
|
| Send email to the article author |
|
|
